Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Q3 2025 Management View Guillermo Novo, Chairman & CEO, highlighted the completion of portfolio optimization and stated, “We ...

The Kentucky-based company’s results are a bright spot in what’s otherwise been a gloomy quarter for health insurers. Humana ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Hit by rising medical care costs and squeezed by government changes, the health care conglomerate acknowledges “pricing and operational mistakes” affected its bottom line and has outlined steps to ...

Stock markets were mixed on Tuesday as investors started turning their attention from trade deals to a slew of company ...

Hundreds of tenants from across Massachusetts descended on Beacon Hill Tuesday to show their support for rent stabilization ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Chord Energy Schedules Second Quarter 2025 Earnings Release and Conference Call Provided by PR Newswire Jul 16, 2025, 8:40:00 PM ...

M&T Bank's risk reduction strategy pays off with regulators, as stress test results exceed expectations and criticized loans decrease significantly.